Catecholamine-induced cardiomyopathy

Endocrine Practice

Volumn 14, Issue 9, 2008, Pages 1137-1149

  Kassim, Thaslim Ahamed ^a,b   Clarke, Douglas D ^a   Mai, Vinh Q ^a   Clyde, Patrick W ^a   Shakir, K M Mohamed ^a  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b HOWARD UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CATECHOLAMINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; METIROSINE; PHENOXYBENZAMINE; PHENTOLAMINE; PROPRANOLOL;

ALPHA ADRENERGIC RECEPTOR BLOCKING; ANGIOCARDIOGRAPHY; ANXIETY; CARDIOMYOPATHY; CARDIOTOXICITY; CATECHOLAMINE INDUCED CARDIOMYOPATHY; CONGESTIVE CARDIOMYOPATHY; DYSPNEA; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; FATIGUE; HEART ARREST; HEART ARRHYTHMIA; HEART CATHETERIZATION; HEART HEMODYNAMICS; HEART MUSCLE; HUMAN; HYPERTENSION; HYPOTENSION; LUNG EDEMA; MEDLINE; OXIDATION; OXYGEN THERAPY; PHEOCHROMOCYTOMA; POSTMENOPAUSE; REVIEW; STUNNED HEART MUSCLE; SWEATING; TACHYCARDIA; TAKOTSUBO CARDIOMYOPATHY; THORAX PAIN; THORAX RADIOGRAPHY; ADRENAL TUMOR; ANIMAL; METABOLISM; PATHOLOGY; PREVALENCE; PROGNOSIS;

ADRENAL GLAND NEOPLASMS; ANIMALS; CARDIOMYOPATHIES; CATECHOLAMINES; HUMANS; MYOCARDIUM; PHEOCHROMOCYTOMA; PREVALENCE; PROGNOSIS;

EID: 64049085622     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/EP.14.9.1137     Document Type: Review

References (127)

1. Sever PS, Roberts JC, Snell ME. Phaeochromocytoma. Clin Endocrinol Metab. 1980;9:543-568.
2. Sardesai SH, Mourant AJ, Sivathandon Y, Farrow R, Gibbons DO. Phaeochromocytoma and catecholamine induced cardiomyopathy presenting as heart failure. Br Heart J. 1990;63:234-237.
3. Bravo EL, Tagle R. Pheochromocytoma: state-of-the-art and future prospects. Endocr Rev. 2003;24:539-553.
4. Brouwers FM, Lenders JW, Eisenhofer G, Pacak K. Pheochromocytoma as an endocrine emergency. Rev Endocr Metab Disord. 2003;4:121-128.
5. Bloom S. Catecholamine cardiomyopathy. N Engl J Med. 1987;317:900-901.
6. van Iperen CE, Giezen J, Kramer WLM, Lips CJM, Bartelink AKM. Acute dyspnoea resulting from pulmonary oedema as the first sign of a phaeochromocytoma. Respiration. 2001;68:323-326.
7. Surawicz B, Mangiardi ML. Electrocardiogram in endocrine and metabolic disorders. Cardiovasc Clin. 1977;8:243-266.
8. Lyon AR, Rees PSC, Prasad S, Poole-Wilson PA, Harding SE. Stress (takotsubo) cardiomyopathy - a novel pathophysiological hypothesis to explain catecholamine-induced acute myocardial stunning. Nat Clin Pract Cardiovasc Med. 2008;5:22-29.
9. Vural M, Ogel K. Dilated cardiomyopathy associated with toluene abuse. Cardiology. 2006;105:158-161.
10. Dickinson BD, Altman RD, Deitchman SD, Champion HC. Safety of over-the-counter inhalers for asthma: report of the council on scientific affairs. Chest. 2000;118:522-526.
11. Varner KJ, Ogden BA, Delcarpio J, Meleg-Smith S. Cardiovascular responses elicited by the "binge" administration of methamphetamine. J Pharmacol Exp Ther. 2002;301:152-159.
12. Kline IK. Myocardial alterations associated with pheochromocytomas. Am J Pathol. 1961;38:539-551.
13. Van Vliet PD, Burchell HB, Titus JL. Focal myocarditis associated with pheochromocytoma. N Engl J Med. 1966;274:1102-1108.
14. Schürmeyer TH, Engeroff B, Dralle H, von zur Mühlen A. Cardiological effects of catecholamine-secreting tumours. Eur J Clin Invest. 1997;27:189-195.
15. Lang SA, Berenbaum E. Phaeochromocytoma. Can J Anaesth. 1989;36:246-247.
16. Dinçer UD, Güner S, Tay A, et al. Decreased expression of beta1- and beta2-adrenoceptors in human diabetic atrial appendage. Cardiovasc Diabetol. 2003;2:6.
17. Brouri F, Findji L, Mediani O, et al. Toxic cardiac effects of catecholamines: role of beta-adrenoceptor downregulation. Eur J Pharmacol. 2002;456:69-75.
18. Engelhardt S, Hein L, Wiesmann F, Lohse MJ. Progressive hypertrophy and heart failure in beta1-adrenergic receptor transgenic mice. Proc Natl Acad Sci USA. 1999;96:7059-7064.
19. Fripp RR, Lee JC, Downing SE. Inotropic responsiveness of the heart in catecholamine cardiomyopathy. Am Heart J. 1981;101:17-21.
20. Fleckenstein A, Janke J, Doring HJ, Pachinger O. Ca overload as the determinant factor in the production of catecholamine induced myocardial lesion. In: Bajusz E, Rona G, Brink AJ, Lochner A, eds. Recent Advances in Studies on Cardiac Structure and Metabolism. Vol 2. Baltimore, MD: University Park Press, 1973: 455-466.
21. Bloom S, Davis DL. Calcium as mediator of isoproterenol-induced myocardial necrosis. Am J Pathol. 1972;69:459-470.
22. Rona G. Catecholamine cardiotoxicity. J Mol Cell Cardiol. 1985;17:291-306.
23. Rona G, Kahn DS, Chappel CI. Studies on infarct-like myocardial necrosis produced by isoproterenol: a review. Rev Can Biol. 1963;22:241-255.
24. Singal PK, Khaper N, Palace V, Kumar D. The role of oxidative stress in the genesis of heart disease. Cardiovasc Res. 1998;40:426-432.
25. Naeije R, Yernault JC, Goldstein M, Corhil A. Acute pulmonary oedema in a patient with phaeochromocytoma. Intensive Care Med. 1978;4:165-167.
26. Downing SE, Chen V. Myocardial injury following endogenous catecholamine release in rabbits. J Mol Cell Cardiol. 1985;17:377-387.
27. Jiang JP, Downing SE. Catecholamine cardiomyopathy: review and analysis of pathogenetic mechanisms. Yale J Biol Med. 1990;63:581-591.
28. Simons M, Downing SE. Coronary vasoconstriction and catecholamine cardiomyopathy. Am Heart J. 1985;109: 297-304.
29. de Leeuw PW, Waltman FL, Birkenhäger WH. Noncardiogenic pulmonary edema as the sole manifestation of pheochromocytoma. Hypertension. 1986;8:810-812.
30. Takeshita T, Shima H, Oishi S,Machida N, Uchiyama K. Noncardiogenic pulmonary edema as the first manifestation of pheochromocytoma: a case report. Radiat Med. 2005;23:133-138.
31. Theodore J, Robin ED. Pathogenesis of neurogenic pulmonary oedema. Lancet. 1975;2:749-751.
32. Rockman HA, Choi DJ, Akhter SA, et al. Control of myocardial contractile function by the level of beta-adrenergic receptor kinase 1 in gene-targeted mice. J Biol Chem. 1998;273:18180-18184.
33. Redfield MM, Kay GN, Jenkins LS, Mianulli M, Jensen DN, Ellenbogen KA. Tachycardia-related cardiomyopathy: a common cause of ventricular dysfunction in patients with atrial fibrillation referred for atrioventricular ablation. Mayo Clin Proc. 2000;75:790-795.
34. Schifferdecker B, Kodali D, Hausner E, Aragam J. Adrenergic shock - an overlooked clinical entity? Cardiol Rev. 2005;13:69-72.
35. Jacob JL, da Silveira LC, de Freitas CG, Cêntola CA, Nicolau JC, Lorga AM. Pheochromocytoma with echocardiographic features of obstructive hypertrophic cardiomyopathy: a case report. Angiology. 1994;45:985-989.
36. Dagartzikas MI, Sprague K, Carter G, Tobias JD. Cerebrovascular event, dilated cardiomyopathy, and pheochromocytoma. Pediatr Emerg Care. 2002;18:33-35.
37. Westphal M, Booke M, Dinh-Xuan AT. Adrenomedullin: a small road from pheochromocytoma to treatment of pulmonary hypertension. Eur Respir J. 2004;24: 518-520.
38. Small KM, Wagoner LE, Levin AM, Kardia SL, Liggett SB. Synergistic polymorphisms of beta1- and alpha2C-adrenergic receptors and risk of congestive heart failure. N Engl J Med. 2002;347:1135-1142.
39. Szakacs JE, Cannon A. L-Norepinephrine myocarditis. Am J Clin Pathol. 1958;30:425-434.
40. Aretz HT, Billingham ME, Edwards WD, et al. Myocarditis: a histopathologic definition and classification. Am J Cardiovasc Pathol. 1987;1:3-14.
41. Frustaci A, Loperfido F, Gentiloni N, Caldarulo M, Morgante E, Russo MA. Catecholamine-induced cardiomyopathy in multiple endocrine neoplasia: a histologic, ultrastructural, and biochemical study. Chest. 1991; 99:382-385.
42. Rosenbaum JS, Billingham ME, Ginsburg R, Tsujimoto G, Lurie KG, Hoffman BB. Cardiomyopathy in a rat model of pheochromocytoma: morphological and functional alterations. Am J Cardiovasc Pathol. 1988;1:389-399.
43. Russo MA, Cittadini A, Dani AM, Inesi G, Terranova T. An ultrastructural study of calcium induced degenerative changes in dissociated heart cells. J Mol Cell Cardiol. 1981;13:265-279.
44. Engelman K. Phaeochromocytoma. Clin Endocrinol Metab. 1977;6:769-797.
45. Shaw TRD, Rafferty P, Tait GW. Transient shock and myocardial impairment caused by phaeochromocytoma crisis. Br Heart J. 1987;57:194-198.
46. Wilkenfeld C, Cohen M, Lansman SL, et al. Heart transplantation for end-stage cardiomyopathy caused by an occult pheochromocytoma. J Heart Lung Transplant. 1992;11(2, pt 1):363-366.
47. Gatzoulis KA, Tolis G, Theopistou A, Gialafos JH, Toutouzas PK. Cardiomyopathy due to a pheochromocytoma: a reversible entity. Acta Cardiol. 1998;53:227-229.
48. Baker G, Zeller NH,Weitzner S, Leach JK. Pheochromocytoma without hypertension presenting as cardiomyopathy. Am Heart J. 1972;83:688-693.
49. Velasquez G, D'Souza VJ, Hackshaw BT, Glass TA, Formanek AG. Phaeochromocytoma and cardiomyopathy. Br J Radiol. 1984;57:89-92.
50. Garcia R, Jennings JM. Pheochromocytoma masquerading as a cardiomyopathy. Am J Cardiol. 1972;29: 568-571.
51. Schaffer MS, Zuberbuhler P, Wilson G, Rose V, Duncan WJ, Rowe RD. Catecholamine cardiomyopathy: an unusual presentation of pheochromocytoma in children. J Pediatr. 1981;99:276-279.
52. Kizer JR, Koniaris LS, Edelman JD, St John Sutton MG. Pheochromocytoma crisis, cardiomyopathy, and hemodynamic collapse. Chest. 2000;118:1221-1223.
53. Lee YH, Lee HD, Lee YA, et al. Ganglioneuroblastoma presenting as dilated cardiomyopathy. Arch Dis Child. 2003;88:162-164.
54. Fauvre FM, John DR, Watkins LE. Cardiomyopathy secondary to pheochromocytoma. Calif Med. 1972;117:58-60.
55. Sadowski D, Cujec B, McMeekin JD, Wilson TW. Reversibility of catecholamine-induced cardiomyopathy in a woman with pheochromocytoma. CMAJ. 1989;141: 923-924.
56. Salathe M,Weiss P, Ritz R. Rapid reversal of heart failure in a patient with phaeochromocytoma and catecholamine-induced cardiomyopathy who was treated with captopril. Br Heart J. 1992;68:527-528
57. Lam JB, Shub C, Sheps SG. Reversible dilatation of hypertrophied left ventricle in pheochromocytoma: serial two-dimensional echocardiographic observations. Am Heart J. 1985;109(3, pt 1):613-615.
58. Imperato-McGinley J, Gautier T, Ehlers K, Zullo MA, Goldstein DS, Vaughan ED Jr. Reversibility of catecholamine-induced dilated cardiomyopathy in a child with a pheochromocytoma. N Engl J Med. 1987;316:793-797.
59. Kim J, Reutrakul S, Davis DB, Kaplan EL, Refetoff S. Multiple endocrine neoplasia 2A syndrome presenting as peripartum cardiomyopathy due to catecholamine excess. Eur J Endocrinol. 2004;151:771-777.
60. Tuǧ T, Özdemir N, Bulut V, Karaoǧlu A, Muz MH. A case of pheochromocytoma manifested as noncardiogenic pulmonary edema. Tr J Med Sci. 1999;29:71-74.
61. Joshi R, Manni A. Pheochromocytoma manifested as noncardiogenic pulmonary edema. South Med J. 1993; 86:826-828.
62. Sanchez-Recalde A, Costero O, Oliver JM, Iborra C, Ruiz E, Sobrino JA. Pheochromocytoma-related cardiomyopathy; inverted takotsubo contractile pattern. Circulation. 2006;113:e738-e739.
63. Michaels RD, Hays JH, O'Brian JT, Shakir KM. Pheochromocytoma associated ventricular tachycardia blocked with atenolol. J Endocrinol Invest. 1990;13:943-947.
64. Grossman E, Knecht A, Holtzman E, Nussinovich N, Rosenthal T. Uncommon presentation of pheochromocytoma: case studies. Angiology. 1985;36:759-765.
65. Carron P, Milliet N, Périat M, Suva F, Blanc MH, Urthaler F. Myocardial stunning in a patient with occult pheochromocytoma. Kardiovaskuläre Medizin. 2004;7: 291-297.
66. Takizawa M, Kobayakawa N, Uozumi H, et al. A case of transient left ventricular ballooning with pheochromocytoma, supporting pathogenetic role of catecholamines in stress-induced cardiomyopathy or takotsubo cardiomyopathy. Int J Cardiol. 2007;114:e15-e17.
67. Siddik-Sayyid SM, Dabbous AS, Shaaban JA, Daaboul DG, Baraka AS. Catastrophic cardiac hypokinesis and multiple-organ failure after surgery in a patient with an undiagnosed pheochromocytoma: emergency excision of the tumor. J Cardiothorac Vasc Anesth. 2007; 21:863-866.
68. Sizemore GW, Scrogin KE, Weisenberg ES, Weldon-Linne CM, Madoo OB. Hypertensive crisis, catecholamine cardiomyopathy, and death associated with pseudoephedrine use in a patient with pheochromocytoma. Endocr Pract. 2008;14:93-96.
69. McGonigle P,Webb SW, Adgey AA. Phaeochro-mocytoma: an unusual cause of chest pain. Br Med J (Clin Res Ed). 1983;286:1477-1478.
70. Cheng TO, Bashour TT. Striking electrocardiographic changes associated with pheochromocytoma: masquerading as ischemic heart disease. Chest. 1976;70:397-399.
71. Haas GJ, Tzagournis M, Boudoulas H. Pheochromocytoma: catecholamine-mediated electrocardiographic changes mimicking ischemia. Am Heart J. 1988;116(5,pt 1):1363-1365.
72. Miller AJ, Cheng TO, Freedman ME. Electro-cardiographic changes during norepinephrine induced hypertension in normal man. Am Heart J. 1955;50:567-576.
73. Ma RC, Yip GW, Chow CC, Cockram CS. A woman with recurrent cardiac ischemia without coronary artery disease. CMAJ. 2007;176:171-173.
74. Manger WM, Hoffman BB. Heart imaging in the diagnosis of pheochromocytoma and assessment of catecholamine uptake. J Nucl Med. 1983;24:1194-1196.
75. Nakajo M, Shapiro B, Glowniak J, Sisson JC, Beierwaltes WH. Inverse relationship between cardiac accumulation of meta-[131I] iodobenzylguanidine (I-131 MIBG) and circulating catecholamines in suspected pheochromocytoma. J Nucl Med. 1983;24:1127-1134.
76. Pacak K. Preoperative management of the pheochromocytoma patient. J Clin Endocrinol Metab. 2007;92:4069-4079.
77. Mishra AK, Agarwal G, Kapoor A, Agarwal A, Bhatia E, Mishra SK. Catecholamine cardiomyopathy in bilateral malignant pheochromocytoma: successful reversal after surgery. Int J Cardiol. 2000;76:89-90.
78. Dzau VJ. Cardiac renin-angiotensin system: molecular and functional aspects. Am J Med. 1988;84:22-27.
79. Singal PK, Kapur N, Dhillon KS, Beamish RE, Dhalla NS. Role of free radicals in catecholamine-induced cardiomyopathy. Can J Physiol Pharmacol. 1982;60:1390-1397.
80. Przyklenk K, Kloner RA. Relation between structure and effects of ACE inhibitors: comparative effects in myocardial ischemic/reperfusion injury. Br J Clin Pharmacol. 1989;28(suppl 2):167S-175S.
81. Favre L, Vallotton MB. Nifedipine in pheochromocytoma. Ann Intern Med. 1986;104:125.
82. Proye C, Thevenin D, Cecat P, et al. Exclusive use of calcium channel blockers in preoperative and intraoperative control of pheochromocytomas: hemodynamics and free catecholamine assays in ten consecutive patients. Surgery. 1989;106:1149-1154.
83. KinneyMA, Narr BJ,Warner MA. Perioperative management of pheochromocytoma. J Cardiothorac Vasc Anesth. 2002;16:359-369.
84. Iliopoulos O, Chan-Smutko G, Gonzalez RG, Louis DN, Stone JR. Case records of the Massachusetts General Hospital: case 23-2006; a 36-year-old man with numbness in the left [corrected] hand and hypertension [published correction appears in N Engl J Med. 2006;355:1184]. N Engl J Med. 2006;355:394-402.
85. BrownMD, Hudlická O. Protective effects of long-term bradycardial pacing against catecholamine-induced myocardial damage in rabbit hearts. Circ Res. 1988;62: 965-974.
86. Wright AJ, Hudlicka O, Brown MD. Beneficial effect of chronic bradycardial pacing on capillary growth and heart performance in volume overload heart hypertrophy. Circ Res. 1989;64:1205-1212.
87. Hudlicka O, Wright AJ. Capillary diffusion capacity in long-term bradycardially paced rabbit hearts [abstract]. Int J Microcirc Clin Exp. 1987;5:395.
88. Freedman AM, Atrakchi AH, Cassidy MM, Weglicki WB. Magnesium deficiency-induced cardiomyopathy: protection by vitamin E. Biochem Biophys Res Commun. 1990;170:1102-1106.
89. Dhalla NS, Temsah RM, Netticadan T. Role of oxidative stress in cardiovascular diseases. J Hypertens. 2000; 18:655-673.
90. Wood R, Commerford PJ, Rose AG, Tooke A. Reversible catecholamine-induced cardiomyopathy. Am Heart J. 1991;121(2, pt 1):610-613.
91. Abe Y, Kondo M. Apical ballooning of the left ventricle: a distinct entity? Heart. 2003;89:974-976.
92. Akashi YJ, Nakazawa K, Sakakibara M, Miyake F, Koike H, Sasaka K. The clinical features of takotsubo cardiomyopathy. QJM. 2003;96:563-573..
93. Wittstein IS, Thiemann DR, Lima JA, et al. Neurohumoral features of myocardial stunning due to sudden emotional stress. N Engl J Med. 2005;352:539-548.
94. Dote K, Sato H, Tateishi H, Uchida T, Ishihara M. Myocardial stunning due to simultaneous multivessel coronary spasms: a review of 5 cases [article in Japanese]. J Cardiol. 1991;21:203-214.
95. Sakamoto H, Nishimura H, Imataka K, Ieki K, Horie T, Fujii J. Abnormal Q wave, ST-segment elevation, Twave inversion, and widespread focal myocytolysis associated with subarachnoid hemorrhage. Jpn Circ J. 1996;60:254-257.
96. Kurisu S, Sato H, Kawagoe T, et al. Tako-tsubo-like left ventricular dysfunction with ST-segment elevation: a novel cardiac syndrome mimicking acute myocardial infarction. Am Heart J. 2002;143:448-455.
97. Goldstein DS, Eisenhofer G, Kopin IJ. Sources and significance of plasma levels of catechols and their metabolites in humans. J Pharmacol Exp Ther. 2003;305: 800-811.
98. Saeki S, Matsuse H, Nakata H, Fukahori S, Miyahara Y, Kohno S. A case of bronchial asthma complicated with takotsubo cardiomyopathy after frequent epinephrine medication [article in Japanese]. Nihon Kokyuki Gakkai Zasshi. 2006;44:701-705.
99. Lacy CR, Contrada RJ, Robbins ML, et al. Coronary vasoconstriction induced by mental stress (simulated public speaking). Am J Cardiol. 1995;75:503-505.
100. Kurisu S, Inoue I, Kawagoe T, et al. Documentation of early improvement of left ventricular function in takotsubo cardiomyopathy. Int J Cardiol. 2007;114:E70-E72.
101. Bybee KA, Kara T, Prasad A, et al. Systematic review: transient left ventricular apical ballooning; a syndrome that mimics ST-segment elevation myocardial infarction. Ann Intern Med. 2004;141:858-865.
102. Akashi YJ, Nakazawa K, Sakakibara M, Miyake F, Musha H, Sasaka K. 123I-MIBG myocardial scintigraphy in patients with "takotsubo" cardiomyopathy. J Nucl Med. 2004;45:1121-1127.
103. Merli E, Sutcliffe S, Gori M, Sutherland GG. Takotsubo cardiomyopathy: new insights into the possible underlying pathophysiology. Eur J Echocardiogr. 2006; 7:53-61.
104. Mori H, Ishikawa S, Kojima S, et al. Increased responsiveness of left ventricular apical myocardium to adrenergic stimuli. Cardiovasc Res. 1993;27:192-198.
105. Hinojosa-Laborde C, Chapa I, Lange D, Haywood JR. Gender differences in sympathetic nervous system regulation. Clin Exp Pharmacol Physiol. 1999;26:122-126.
106. Yoshida T, Hibino T, Kako N, et al. A pathophysiologic study of tako-tsubo cardiomyopathy with F-18 fluorodeoxyglucose positron emission tomography. Eur Heart J. 2007;28:2598-2604.
107. Tsuchihashi K, Ueshima K, Uchida T, et al (Angina Pectoris-Myocardial Infarction Investigations in Japan). Transient left ventricular apical ballooning without coronary artery stenosis: a novel heart syndrome mimicking acute myocardial infarction. J Am Coll Cardiol. 2001;38:11-18.
108. Sharkey SW, Lesser JR, Zenovich AG, et al. Acute and reversible cardiomyopathy provoked by stress in women from the United States. Circulation. 2005;111:472-479.
109. Pillière R, Mansencal N, Digne F, Lacombe P, Joseph T, Dubourg O. Prevalence of tako-tsubo syndrome in a large urban agglomeration. Am J Cardiol. 2006;98:662-665.
110. Abdulla I, Kay S, Mussap C, et al. Apical sparing in tako-tsubo cardiomyopathy. Intern Med J. 2006;36:414-418.
111. Kurisu S, Inoue I, Kawagoe T, et al. Left ventricular apical thrombus formation in a patient with suspected tako-tsubo-like left ventricular dysfunction. Circ J. 2003; 67:556-558.
112. Ohara Y, Hiasa Y, Hosokawa S, et al. Left ventricular free wall rupture in transient left ventricular apical ballooning. Circ J. 2005;69:621-623.
113. Dec GW. Recognition of the apical ballooning syndrome in the United States. Circulation. 2005;111:388-390.
114. Abdulla I,Ward MR. Tako-tsubo cardiomyopathy: how stress can mimic acute coronary artery occlusion. Med J Aust. 2007;187:357-360.
115. Padayachee L. Levosimendan: the inotrope of choice in cardiogenic shock secondary to takotsubo cardiomyopathy? Heart Lung Circ. 2007;16(suppl 3):S65-S70.
116. Siostrzonek P, Koreny M, Delle-Karth G, Haumer M, Koller-Strametz J, Heinz G. Milrinone therapy in catecholamine-dependent critically ill patients with heart failure. Acta Anaesthesiol Scand. 2000;44:403-409.
117. Cavana M, Pignataro C, Fraticelli A, Mebazaa A. The clinical experience with levosimendan in anesthesiology and in the intensive care unit. Ital Heart J. 2003;4(suppl 2):61S-64S.
118. Michaels AD, McKeown B, Kostal M, et al. Effects of intravenous levosimendan on human coronary vasomotor regulation, left ventricular wall stress, and myocardial oxygen uptake. Circulation. 2005;111:1504-1509.
119. Elesber AA, Prasad A, Lennon RJ, Wright RS, Lerman A, Rihal CS. Four-year recurrence rate and prognosis of the apical ballooning syndrome. J Am Coll Cardiol. 2007;50:448-452.
120. Gueron M, Yaron R. Cardiovascular manifestations of severe scorpion sting: clinicopathologic correlations. Chest. 1970;57:156-162.
121. Sato Y, Tanaka M, Nishikawa T. Reversible catecholamine-induced cardiomyopathy by subcutaneous injections of epinephrine solution in an anesthetized patient. Anesthesiology. 2000;92:615-619.
122. Fyfe AI, Daly PA, Dorian P, Tough J. Reversible "cardiomyopathy" after accidental adrenaline overdose. Am J Cardiol. 1991;67:318-319.
123. Naik SD, Freudenberger RS. Ephedra-associated cardiomyopathy. Ann Pharmacother. 2004;38:400-403.
124. McLeod AA, Marjot R, Monaghan MJ, Hugh-Jones P, Jackson G. Chronic cardiac toxicity after inhalation of 1,1,1-trichloroethane. Br Med J (Clin Res Ed). 1987;294: 727-729.
125. Muller-Werdan U, Buerke M, Ebelt H, et al. Septic cardiomyopathy - a not yet discovered cardiomyopathy? Exp Clin Cardiol. 2006;11:226-236.
126. Pizon AF, Lovecchio F. Reversible cardiomyopathy complicating intrathecal baclofen withdrawal: a case report. J Med Toxicol. 2007;3:187-189.
127. Satoh H, Tateishi H, Uchida T. Takotsubo-type cardiomyopathy due to multivessel spasm. In: Kodama K, Haze K, Hon M, eds. Clinical Aspects of Myocardial Injury: From Ischemia to Heart Failure [in Japanese]. Tokyo, Japan: Kagakuyouronsya Co., 1990: 56-64.